Health TrialsbyHealthPanel

Pantoprazole in Cisplatin Nephrotoxicity

ConditionOncology
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorSherief Abd-Elsalam

About this trial

Pantoprazole in Cisplatin Nephrotoxicity

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with head and neck cancer

Disqualifiers

GFR less than 59.

DM

Elevated liver enzymes more than 3 fold.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Pantoprazole low dose

    Drug

    Pantoprazole 0.6 mg/kg

  • Pantoprazole high dose

    Drug

    Pantoprazole 1.6 mg\\kg

  • Standard hydration

    Other intervention

    Standard hydration alone

  • Cisplatin

    Drug

    Cisplatin

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Standard hydration aloneActive comparator 2 interventions
Group B: Pantoprazole high doseActive comparator 3 interventions
Group C: Pantoprazole Low doseActive comparator 3 interventions

Trial outcomes

Primary outcomes

1

Number of patients with no renal toxicity

The number of patients with no renal toxicity

Time frame
6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sherief Abd-Elsalam

Lead sponsor

Tanta University

Sponsor institution

Source ClinicalTrials.gov
Apply now